Category Reports Biotech

Tickers reports and analysis

AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.

Biotech Radar — July 11, 2026: Chemomab, CervoMed and AtaiBeckley — $CMMB $CRVO $ATAI

Biotech

Today’s radar compares three very different catalyst structures: Chemomab’s proposed merger with Scipher Medicine and shift toward AI-guided rheumatoid arthritis development, CervoMed’s completed Phase 2a enrollment in nonfluent variant primary progressive aphasia, and AtaiBeckley’s completion of dosing in the VLS-01 Phase 2b Elumina trial ahead of a Q4 2026 topline readout.

Biotech Radar July 1, 2026: $CANF, $ABVX, $SXTP and $MODD Lead Today’s Catalyst Watch

Biotech

Today’s biotech tape is not built around one single mega-cap headline. It is a classic catalyst radar session: one small oncology name with a fresh Phase 2a survival signal, one late-stage inflammatory disease story with a major Phase 3/NDA setup but financing pressure, one infectious-disease micro-cap tied to babesiosis development, and one diabetes medtech name moving from clearance into real-world use.

AI in Biotech 2026 $RXRX $TEM $EXAI

AI in Biotech: Conceptual AI-assisted biotechnology research with molecular models and a microscope.

Recursion, Tempus AI and Exscientia are three “pure-play” examples of what it really means to put artificial intelligence at the centre of a biotech business model. Used properly, AI can compress timelines, surface non-obvious biology and make better use of messy data. Used badly, it can amplify errors, burn cash faster and create stories the clinic will never confirm.

Cognition Therapeutics $CGTX

CGTX: Conceptual neuroscience research illustrated by a brain, synapse and molecular model.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative, small-molecule oligomer antagonists for age-related degenerative disorders of the central nervous system, primarily Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB).

ALVO Alvotech Feb 2026

Conceptual biosimilar research with a protein structure, vial and bioprocessing equipment.

Alvotech is not a typical development-stage biotech: it is a vertically integrated biosimilar platform that already generates hundreds of millions of dollars in revenue from launched products like AVT02 (adalimumab) and AVT04 (ustekinumab), while also running a crowded late-stage pipeline. The stock sits in that awkward middle ground between “early growth” and “heavy balance sheet”, with over 1B$ of debt but also positive adjusted EBITDA and operating profit in the latest 9-month period.